Shared portfolio
Public Portfolio Challenge: Semis + Biotech
Explore Public Portfolio Challenge: Semis + Biotech on NexusTrade: portfolio performance, risk metrics, and the creator's strategy notes.
Episode 11 live forward test.
On August 26, 2026, the original six-strategy XBI/SMH design was preserved in a separate paper portfolio and this live Public account was replaced with the validated 29-strategy implementation: one central allocator across 26 thesis-approved companies, two global option exits, and 26 company-specific exits.
There is no XBI gate, no SMH gate, and no special MRNA or ANET allocation. Each company must be above its own 100-day SMA with positive 63-day momentum. Eligible names compete on 126-day return and are weighted by 63-day return divided by 63-day volatility. Entries are single long calls with 270 to 730 DTE, capped at 6% per company and 45% per rebalance. VIX must be below 35 and option gross exposure must be below 39% before a new buying cycle. Profit, time, and company-level trend exits remain active.
Research evidence at the actual $13,500 account size: four of five OOS folds profitable, +25.00% median OOS return, 1.99 median OOS Sortino, and 22.47% worst OOS drawdown. The full March 2022 to April 2026 replay returned +252.37% with a 29.79% maximum drawdown, 30.53% median deployment, 20 of 26 names traded, and 496 simulated option fills. These are historical simulations, not promised returns.
Deployment preserved the existing QGEN Dec. 17, 2027 $45 call. A current-book reconciliation at $13,335.02 NAV produced zero orders and $0 estimated cost. Automatic approval is off. Every future live order requires manual approval.
Episode 11: https://nexustrade.io/blog/moderna-basically-cured-cancer-i-used-grok-bot-to-create-a-trading-strategy-20260823
Research record: https://github.com/austin-starks/Public-Portfolio-Challenge/blob/main/episode-11/addendum/EPISODE_11_OPTIONS_PORTFOLIO_REDESIGN_20260826.md
Enable JavaScript to view the interactive performance dashboard.